Isomorphic Labs has secured a $2.1 billion Series B funding round, a significant follow-on to its $600 million Series A in May of last year. The round was led by Thrive Capital with participation from Alphabet, GV, Temasek, CapitalG, and the UK Sovereign AI Fund. These funds will accelerate the development and deployment of its AI drug design engine, IsoDDE, and expand its therapeutic pipeline for cancer and immune disorders, while also enabling the recruitment of specialized talent.
Amount: $2.1B
